MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Celldex Therapeutics Company Profile (NASDAQ:CLDX)

Consensus Ratings for Celldex Therapeutics (NASDAQ:CLDX) (?)
Ratings Breakdown: 8 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $36.50 (402.75% upside)

Analysts' Ratings History for Celldex Therapeutics (NASDAQ:CLDX)
Show:
DateFirmActionRatingPrice TargetActions
11/24/2015Roth CapitalInitiated Coverage$39.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/9/2015Brean CapitalReiterated RatingBuy$31.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/15/2015Cowen and CompanyReiterated RatingBuy$28.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/27/2015Roth CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/14/2015Leerink SwannReiterated RatingOutperform$45.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/11/2015Cowen and CompanyReiterated RatingOutperform$34.00 -> $28.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/11/2015Cantor FitzgeraldLower Price TargetBuy$38.00 -> $31.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/11/2015OppenheimerLower Price TargetOutperform$45.00 -> $42.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/11/2015Brean CapitalLower Price TargetBuy$35.00 -> $31.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/11/2015Roth CapitalLower Price TargetBuy$43.00 -> $39.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/30/2015OppenheimerReiterated RatingBuy$45.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/30/2015Roth CapitalReiterated RatingBuy$43.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/2/2015Brean CapitalReiterated RatingBuy$35.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/2/2015Cantor FitzgeraldReiterated RatingBuy$38.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/1/2015WBB SecuritiesReiterated RatingBuy$30.00 -> $40.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/1/2015Cowen and CompanySet Price TargetBuy$33.00 -> $34.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/5/2015Cantor FitzgeraldReiterated RatingBuy$38.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/18/2015Jefferies GroupReiterated RatingBuy$24.00 -> $36.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/11/2015Cantor FitzgeraldBoost Price TargetBuy$33.00 -> $38.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/23/2015Cowen and CompanySet Price TargetBuy$26.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/19/2014Cantor FitzgeraldSet Price TargetBuy$33.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/17/2014OppenheimerReiterated Rating$36.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/17/2014Roth CapitalBoost Price TargetBuy$40.00 -> $43.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/26/2014Cowen and CompanyInitiated CoverageOutperform$22.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/28/2014Ned Davis ResearchUpgradeSell -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/4/2014Jefferies GroupBoost Price TargetBuy$29.00 -> $31.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/4/2014Cantor FitzgeraldReiterated RatingBuy$39.00 -> $33.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/4/2014OppenheimerLower Price TargetOutperform$40.00 -> $36.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 2/6/2014 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha